WEBULL
News
HOTH
0.8082
+4.95%
0.0381
Hoth Therapeutics confirms it holds no cryptocurrency assets
TipRanks · 3d ago
Hoth Therapeutics Confirms It Holds No Cryptocurrency Assets
Reuters · 3d ago
HOTH THERAPEUTICS ADDRESSES MARKET RUMOR, HOTH HOLDS NO CRYPTO CURRENCY ASSETS
Reuters · 3d ago
Weekly Report: what happened at HOTH last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at HOTH last week (0119-0123)?
Weekly Report · 01/26 09:25
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Benzinga · 01/22 17:47
Hoth Therapeutics’ HT-001 shows 100% response in EFGR-treated cancer patients
TipRanks · 01/22 13:27
Hoth Therapeutics Announced Interim Results From The Open-Label Pharmacokinetic Cohort Of Its Ongoing CLEER-001 Clinical Trial Evaluating HT-001 In Cancer Patients Receiving EGFR Inhibitor Therapy; Primary Endpoint ARIGA Improved By ~50% From Baseline By Week 6, With All Evaluable Patients Reaching Low-severity Disease; Additional Endpoints Demonstrated ~34% Improvement In Oncology Toxicity And ~37% Reduction In Patient-Reported Pruritus
Benzinga · 01/22 13:16
Hoth Therapeutics Reports 100% Clinical Response in HT-001 Trial for EGFR-Treated Cancer Patients
Reuters · 01/22 13:13
HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY
Reuters · 01/22 13:13
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 01/21 21:05
Hoth Therapeutics receives approval for HT-KIT cancer program patent in China
TipRanks · 01/21 13:21
Hoth Therapeutics Receives Patent Coverage From China National Intellectual Property Administration Covering HT-KIT Cancer Program
Benzinga · 01/21 13:18
Hoth Therapeutics Secures Chinese Patent for HT-KIT Cancer Program, Strengthening Global Oncology IP Portfolio
Reuters · 01/21 13:13
Weekly Report: what happened at HOTH last week (0112-0116)?
Weekly Report · 01/19 09:28
Hoth Therapeutics highlights obesity and pipeline progress to regulators
TipRanks · 01/16 13:28
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/15 21:05
Hoth Therapeutics Reaches European Regulatory Milestone For HT-001 Clinical Program Targeting Cancer Patients Undergoing EGFR Inhibitor Therapies
Benzinga · 01/15 13:19
HOTH THERAPEUTICS : COUNTRY-SPECIFIC PART II REGULATORY DECISIONS IN HUNGARY, SPAIN, & POLAND ARE EXPECTED BY JAN 19, 2026
Reuters · 01/15 13:17
Hoth Therapeutics Receives Positive EU Regulatory Conclusion for HT-001 Oncology Trial
Reuters · 01/15 13:17
More
Webull provides a variety of real-time HOTH stock news. You can receive the latest news about Hoth Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HOTH
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).